Skip to main content

Table 3 Characteristics of patients who used methotrexate (MTX) and presented adverse drug reactions (ADRs)

From: Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort

Variable ADRs of MTX (N = 398)
Yes No ρ*
n = 252 n = 146  
Sex (%)
 Female 174 (63.3) 101 (36.7) 0.978
 Male 78 (63.4) 45 (36.6)  
Age (years) – Cohort in median
  ≤ 16 236 (72.6) 89 (27.4) <  0.001
>  16 16 (21.9) 57 (78.1)  
Route of administration of MTX (%)
 Subcutaneous 40 (62.5) 24 (37.5) 0.882
 Oral 212 (63.5) 122 (36.5)  
Dose of MTX (mg/kg/week)
  ≥ 0.6 175 (69.7) 76 (30.3) 0.001
  < 0.6 77 (52.4) 70 (47.6)  
Disease (%)
 JIA 207 (68.1) 97 (31.9) 0.001
 JSLE 20 (57.1) 15 (42.9)  
 JDM 25 (42.4) 34 (57.6)  
  1. N - number of patients treated with MTX, JIA - juvenile idiopathic arthritis, JSLE - juvenile systemic lupus erythematosus, JDM - juvenile dermatomyositis
  2. * Chi Pearson square or Fisher’s exact. P < 0.05